phrykt

Pyxis Oncology, Inc. (PYXS): who owns it and who trades it

As of Nov 16, 2026, PYXS insiders reported 1 open-market sale worth $107K and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Jakob Dupont (Director), with $107K. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Pyxis Oncology

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns PYXS

76 funds and institutions reported PYXS shares worth $101M at the end of Q2 2026, about 54% of the company. The largest holder is GordonMD Global Investments LP with 16.0%.

Funds and institutions (13F) 54%Everyone else 46%

10 largest owners, by share of the company

GordonMD Global Investments LP16.0%
Pfizer Inc11.2%
Laurion Capital Management LP7.8%
Vanguard Capital Management LLC3.3%
Atle Fund Management AB1.5%
BlackRock, Inc.1.4%
Palo Alto Investors LP1.4%
Marshall Wace, LLP1.3%
Renaissance Technologies LLC1.2%
Geode Capital Management, LLC0.9%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
GordonMD Global Investments LP10.02M15.96%$30.2M+143%
Pfizer Inc7.03M11.19%$19.5MNo change
Laurion Capital Management LP4.90M7.80%$14.8M-2%
Vanguard Capital Management LLC2.08M3.30%$6.2M+2%
Atle Fund Management AB966,4591.54%$2.9MNew
BlackRock, Inc.867,9341.38%$2.6M+10%
Palo Alto Investors LP864,2771.38%$2.6M-14%
Marshall Wace, LLP830,5441.32%$2.5M+134%
Renaissance Technologies LLC772,2321.23%$2.3M-13%
Geode Capital Management, LLC591,8490.94%$1.8M-1%
Woodline Partners LP523,9990.83%$1.6MNew
683 Capital Management, LLC459,3670.73%$1.4M-49%
Jacobs Levy Equity Management, Inc428,6060.68%$1.3M-7%
Longaeva Partners L.P.353,5820.56%$1.1M-30%
Decheng Capital LLC326,8100.52%$984KNo change
Vanguard Fiduciary Trust Co302,9860.48%$912K+1%
Jane Street Group, LLC290,0900.46%$873K-5%
State Street Corp248,8370.40%$749KNo change
Millennium Management LLC233,0040.37%$701K-41%
UBS Group AG155,2170.25%$467K-39%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, PYXS insiders reported $0 of open-market purchases and $107K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$107K
1 trades, 1 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Jun 30, 2026
Filed Jul 2, 2026

Purchases and sales by month

$107K$107KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Jun 30, 2026Jakob DupontDirectorSale35,000$3.06$107KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Jakob DupontDirector–$107KJun 30, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

PYXS short interest

Moderate short interest. 5.4% of PYXS shares are sold short: about 1 share in 18. Over the last 12 reports the number of shares short went up 150%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 4.53M PYXS shares were sold short, 5.4% of the shares outstanding, up 4.1% from the report before. At the average daily volume of 777,619 shares, buying them all back would take about 5.8 trading days (days to cover).

Shares short, % of all shares

5.43%May 15Oct 307.22%

Days to cover

5.8May 15Oct 307.8

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20264.53M5.43%+4%777,6195.8
Oct 15, 20264.35M5.21%-11%1.25M3.5
Sep 30, 20264.89M5.86%+4%1.21M4.0
Sep 15, 20264.68M5.61%+18%1.28M3.6
Aug 31, 20263.97M4.76%-10%569,9637.0
Aug 14, 20264.43M5.31%+6%2.22M2.0
Jul 31, 20264.17M6.64%+28%996,5324.2
Jul 15, 20263.25M5.18%+42%1.05M3.1
Jun 30, 20262.29M3.64%+14%1.84M1.2
Jun 15, 20262.02M3.21%+16%415,4784.8
May 29, 20261.74M2.77%-4%607,7112.9
May 15, 20261.81M2.88%-9%855,9562.1

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Pyxis Oncology company events

Pyxis Oncology filed 11 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Oct 1, 2026AgreementPyxis Oncology, Inc. entered into an underwriting agreement with Leerink Partners LLC, Guggenheim Securities, LLC and Wells Fargo Securities, LLC, as representatives of the several underwriters named therein, relating to an underwritten public offering of (i) (a) 36,047,919 shares of the Company’s… Filing
  3. Sep 9, 2026AnnouncementThe Company today announced updated data from its ongoing global Phase 1 monotherapy study evaluating micvotabart pelidotin (MICVO) in patients with second-line and beyond (2L+) recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Filing
  4. Sep 8, 2026LeadershipThe Board of Directors of Pyxis Oncology, Inc. appointed Thomas Civik, the Company’s Interim Chief Executive Officer, to serve as the Company’s permanent Chief Executive Officer, effective immediately. Filing
  5. Aug 13, 2026ResultsReleased financial results. Filing
  6. Jul 2, 2026AgreementPyxis Oncology, Inc. entered into a securities purchase agreement for a private placement with certain institutional and accredited investors (each, a “Purchaser” and collectively, the “Purchasers”). Filing
  7. Jun 15, 2026VoteReported shareholder vote results. Filing
  8. May 14, 2026ResultsReleased financial results. Filing
  9. Apr 30, 2026LeadershipAmended an earlier report. The Separation Agreement between the Company and Dr. Sullivan became binding and effective, addressing Dr. Sullivan’s separation from the Company. Filing
  10. Mar 23, 2026ResultsReleased financial results. Filing
  11. Dec 18, 2025AnnouncementThe Company today announced positive preliminary data from its ongoing Phase 1 clinical studies evaluating micvotabart pelidotin (MICVO), a first-in-concept antibody-drug conjugate (ADC) targeting extradomain-B of fibronectin (EDB+FN), a non-cellular structural component of the tumor extracellular… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Pyxis Oncology financials

Famous investors that hold PYXS

4 of the 50 well-known investors we track reported holding PYXS in their latest 13F filing. The largest position is Israel Englander's, worth $1.9M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 2026831,700$1.9M0.0%+257%
George Soros · Soros Fund ManagementQ3 2026476,113$1.1M0.0%New
Jim Simons · Renaissance TechnologiesQ3 2026367,780$857K0.0%-52%
Ken Griffin · Citadel AdvisorsQ3 2026198,431$462K0.0%+319%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 14 filings named PYXS in the last 120 days.

FiledHolderFormStake
Nov 16, 2026OrbiMed Advisors LLC13G3.4%
Nov 16, 2026OrbiMed Advisors LLC13G3.4%
Nov 16, 2026RTW Investments, LP13G9.9%
Nov 16, 2026RTW Investments, LP13G9.9%
Nov 16, 2026BIOTECHNOLOGY VALUE FUND L P13G/A5.2%
Nov 16, 2026BIOTECHNOLOGY VALUE FUND L P13G/A5.2%
Nov 3, 2026Laurion Capital Management LP13G/A5.2%
Nov 3, 2026Laurion Capital Management LP13G/A5.2%
Oct 9, 2026GordonMD Global Investments LP13G/A16.4%
Oct 9, 2026GordonMD Global Investments LP13G/A16.4%
Oct 5, 2026Coastlands Capital LP13G5.4%
Oct 5, 2026Coastlands Capital LP13G5.4%
Oct 2, 2026GordonMD Global Investments LP13G/A17.5%
Oct 2, 2026GordonMD Global Investments LP13G/A17.5%

Questions about Pyxis Oncology, Inc. (PYXS) stock

Who owns the most PYXS stock?

The largest reported owner of Pyxis Oncology, Inc. (PYXS) is GordonMD Global Investments LP, with 16.0% of the company. In total, 76 funds and institutions reported holding PYXS at the end of Q2 2026, together about 54% of the shares. See the largest owners.

Are PYXS insiders buying or selling?

In the last 12 months, PYXS insiders reported no open-market purchases and 1 sale worth $107K. The latest trade was on Jun 30, 2026. See every trade.

What is the short interest in PYXS?

As of Oct 30, 2026, 4.53M PYXS shares were sold short, 5.4% of the shares outstanding, up 4.1% from the report before. At the average daily volume of 777,619 shares, buying them all back would take about 5.8 trading days (days to cover). See the history.

Which famous investors hold PYXS?

4 of the 50 well-known investors we track reported PYXS in their latest 13F filing, including Israel Englander, George Soros, Jim Simons. The largest position is worth $1.9M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.